- Home
- HSHP vs ITOS Comparison
HSHP vs ITOS Comparison
Compare HSHP & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- ITOS
- Stock Information
- Founded
- HSHP 2021
- ITOS 2011
- Country
- HSHP Bermuda
- ITOS United States
- Employees
- HSHP N/A
- ITOS N/A
- Industry
- HSHP
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSHP
- ITOS Health Care
- Exchange
- HSHP Nasdaq
- ITOS Nasdaq
- Market Cap
- HSHP 268.6M
- ITOS 381.2M
- IPO Year
- HSHP 2023
- ITOS 2020
- Fundamental
- Price
- HSHP $6.69
- ITOS $10.26
- Analyst Decision
- HSHP
- ITOS Hold
- Analyst Count
- HSHP 0
- ITOS 6
- Target Price
- HSHP N/A
- ITOS $10.60
- AVG Volume (30 Days)
- HSHP 194.0K
- ITOS 793.1K
- Earning Date
- HSHP 08-20-2025
- ITOS 08-07-2025
- Dividend Yield
- HSHP 6.49%
- ITOS N/A
- EPS Growth
- HSHP 185.76
- ITOS N/A
- EPS
- HSHP 0.28
- ITOS N/A
- Revenue
- HSHP $121,972,000.00
- ITOS $35,000,000.00
- Revenue This Year
- HSHP $11.22
- ITOS N/A
- Revenue Next Year
- HSHP $25.90
- ITOS N/A
- P/E Ratio
- HSHP $25.67
- ITOS N/A
- Revenue Growth
- HSHP 107.17
- ITOS 177.89
- 52 Week Low
- HSHP $4.29
- ITOS $4.80
- 52 Week High
- HSHP $8.74
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- HSHP 65.51
- ITOS 66.97
- Support Level
- HSHP $6.24
- ITOS $10.05
- Resistance Level
- HSHP $6.44
- ITOS $10.21
- Average True Range (ATR)
- HSHP 0.17
- ITOS 0.13
- MACD
- HSHP 0.02
- ITOS -0.06
- Stochastic Oscillator
- HSHP 92.59
- ITOS 81.48
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.